Rybelsus for weight loss: what the before-and-afters don't show

What did @la_adriana01 actually say?

She lost 44 pounds over one year on Rybelsus (oral semaglutide), dropping from 192 to 148 pounds. After stopping, she held steady around 150 for several months before creeping back to 157. She's now off the medication for nearly a year, dealing with returning food cravings, and considering whether to go back to her doctor.

This is a personal weight-loss story, not a medical claim. She's not telling you to take Rybelsus, not dosing you, not selling anything. She's showing before-and-after photos and admitting she's struggling. That framing matters for how we read this: most of what she describes is consistent with how semaglutide actually works, and she's more honest about the limitations than most GLP-1 content on TikTok.

Does the science back this up?

Yes, mostly. A 44-pound loss over 12 months on oral semaglutide is on the higher end but biologically plausible. Weight regain after stopping is not just expected, it's nearly guaranteed, and the science on this is blunt.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) tracked participants for 68 weeks after stopping injectable semaglutide 2.4 mg. Within one year, they regained two-thirds of their lost weight. Oral semaglutide delivers lower and more variable bioavailability than injectable forms, roughly 1% absorption, so weight loss outcomes are generally more modest. The OASIS 1 trial (Davies et al., 2023, The Lancet) showed oral semaglutide 50 mg produced about 15% body weight reduction over 68 weeks in non-diabetic adults. Her 23% loss over 12 months at presumably lower doses is notable but not impossible depending on starting metabolic conditions.

The return of food cravings she describes, what she calls "the munchies," is mechanistically explained. GLP-1 receptor agonists reduce appetite partly through central nervous system signaling in the hypothalamus. When the drug clears, those hunger-suppressing signals go with it.

What did they get wrong (or right)?

She got the core narrative right. Weight comes back when you stop. Cravings return. The drug is not a permanent fix. That's accurate and worth saying clearly because a lot of GLP-1 content skips that part entirely.

Two things are worth flagging. First, she frames regaining 9 pounds over nearly a year as "sucking" and says she's "embarrassed." That framing is understandable but medically misleading by omission. Gaining back a small fraction of lost weight after stopping a powerful appetite-suppressing drug is not a personal failure. It is a predictable pharmacological outcome. The STEP 1 follow-up data is unambiguous: the body's homeostatic mechanisms work against weight maintenance once the drug is gone.

Second, she mentions wanting a "facelift" or "neck lift" for loose skin after weight loss. That's a personal choice, not a medical concern we need to weigh in on. But she notes she's already spoken to a doctor, which is the right step.

She does not make any dangerous claims. She does not recommend dosages, suggest the drug cures diabetes, or compare compounded semaglutide to brand-name products. For TikTok GLP-1 content, that's a higher bar than most creators clear.

What should you actually know?

Rybelsus is FDA-approved for type 2 diabetes, not for weight loss. Wegovy (injectable semaglutide 2.4 mg) is the FDA-approved weight-loss formulation. Doctors can and do prescribe Rybelsus off-label for weight management, which is likely what happened here, but that distinction matters.

Weight regain after stopping GLP-1 medications is not a niche side effect. It is the default outcome. Rubino et al. (2021, NEJM) showed that stopping semaglutide after a treatment period resulted in return of hunger hormones and reversal of metabolic improvements within weeks. Obesity functions like a chronic condition requiring ongoing management, and stopping medication without a maintenance plan is likely to undo progress.

Her instinct, "if I start seeing no difference, I'm just gonna go back to the doctor," is actually the right approach. That conversation, deciding whether to resume, switch medications, or add behavioral support, should happen with a licensed provider who has access to her full history. She seems to understand this. That's worth acknowledging.